The study found that individuals carrying the APOE ε4 allele showed a greater reduction in cardiovascular events and atherosclerosis progression when treated with pravastatin compared to those without this allele, suggesting a potential pharmacogenetic effect of APOE genotype on the therapeutic response to pravastatin in CAD management.[42]. This evidence concerns the gene APOE and coronary artery disorder.